Fundraising FoxBlack Diamond Therapeutics, Inc
NASDAQ: BDTX11 known investors
Find your way into Black Diamond Therapeutics, Inc
Sign up to see every warm intro you have to Black Diamond Therapeutics, Inc
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Black Diamond Therapeutics, Inc team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma. The company uses its proprietary MAP drug discovery platform to identify and selectively inhibit mutant driver proteins while sparing wild-type forms.
Founders & leadership
Investors · 11
How we know: the VCSheet dataset · Not right? Tell us
How we know: the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Nextech Invest's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: Versant Ventures's portfolio page · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
In the news
Frequently asked questions
- What does Black Diamond Therapeutics, Inc do?
- Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma. The company uses its proprietary MAP drug discovery platform to identify and selectively inhibit mutant driver proteins while sparing wild-type forms.
- Who founded Black Diamond Therapeutics, Inc?
- Black Diamond Therapeutics, Inc was founded by Elizabeth Buck.
- Who are Black Diamond Therapeutics, Inc's investors?
- Black Diamond Therapeutics, Inc's investors include LAV, Lilly Asia Ventures, New Enterprise Associates (NEA), Nextech Invest, NSG Ventures, RA Capital, Versant Ventures, Wellington Management and 3 more.
- How much funding has Black Diamond Therapeutics, Inc raised?
- Black Diamond Therapeutics, Inc has disclosed $42.5K raised across 1 round.